GOAL OF WORK: This study was performed to evaluate the clinical features and outcomes of Staphylococcus aureus infection in non-neutropenic cancer patients. MATERIALS AND METHODS: From the database of a surveillance study for S. aureus infections, the data regarding S. aureus infections in non-neutropenic cancer patients were analyzed. MAIN RESULTS: Of 649 non-neutropenic cancer patients with S. aureus infections, 156 (24.0%) had a central venous catheter and 176 (27.1%) had an indwelling urinary catheter. The prevalence of methicillin-resistant S. aureus (MRSA) infections was 54.7% (355 out of 649). As for types of infection, skin and soft tissue infections were the most common (n = 173, 26.7%), followed by pneumonia (n = 165, 25.4%) and primary bacteremia (n = 91; 14.0%). Overall, the 30-day mortality rate was 28.2% (124 out of 440), 34.1% (73 out of 214) in MRSA group, and 22.6% (51 out of 226) in methicillin-sensitive S. aureus group (P = 0.007). When outcomes according to the types of infection were evaluated, the mortality rates were 49.5% (53 out of 107) for pneumonia and 41.2% (49 out of 119) for bacteremia. Multivariate analysis showed that pneumonia, concomitant bacteremia, comorbid liver disease, and intubated state with ICU care were independent risk factors associated with 30-day mortality. CONCLUSION: Our study demonstrated that S. aureus infections in cancer patients are serious clinical conditions with high mortality rates, even in non-neutropenic patients.
GOAL OF WORK: This study was performed to evaluate the clinical features and outcomes of Staphylococcus aureus infection in non-neutropenic cancerpatients. MATERIALS AND METHODS: From the database of a surveillance study for S. aureus infections, the data regarding S. aureus infections in non-neutropenic cancerpatients were analyzed. MAIN RESULTS: Of 649 non-neutropenic cancerpatients with S. aureus infections, 156 (24.0%) had a central venous catheter and 176 (27.1%) had an indwelling urinary catheter. The prevalence of methicillin-resistant S. aureus (MRSA) infections was 54.7% (355 out of 649). As for types of infection, skin and soft tissue infections were the most common (n = 173, 26.7%), followed by pneumonia (n = 165, 25.4%) and primary bacteremia (n = 91; 14.0%). Overall, the 30-day mortality rate was 28.2% (124 out of 440), 34.1% (73 out of 214) in MRSA group, and 22.6% (51 out of 226) in methicillin-sensitive S. aureus group (P = 0.007). When outcomes according to the types of infection were evaluated, the mortality rates were 49.5% (53 out of 107) for pneumonia and 41.2% (49 out of 119) for bacteremia. Multivariate analysis showed that pneumonia, concomitant bacteremia, comorbid liver disease, and intubated state with ICU care were independent risk factors associated with 30-day mortality. CONCLUSION: Our study demonstrated that S. aureus infections in cancerpatients are serious clinical conditions with high mortality rates, even in non-neutropenicpatients.
Authors: Kevin B Laupland; Deirdre L Church; Melissa Mucenski; Lloyd R Sutherland; H Dele Davies Journal: J Infect Dis Date: 2003-04-15 Impact factor: 5.226
Authors: Martin E Stryjewski; Zeina A Kanafani; Vivian H Chu; Paul A Pappas; Tina Harding; Laura A Drew; Daniel K Benjamin; L Barth Reller; Benjamin A Lee; G Ralph Corey; Vance G Fowler Journal: Am J Med Date: 2009-03 Impact factor: 4.965
Authors: Hae Suk Cheong; Cheol-In Kang; Yu Mi Wi; Eun Seok Kim; Jin Seo Lee; Kwan Soo Ko; Doo Ryeon Chung; Nam Yong Lee; Jae-Hoon Song; Kyong Ran Peck Journal: Am J Med Date: 2008-08 Impact factor: 4.965
Authors: Sminil N Mahajan; Jharna N Shah; Ray Hachem; Frank Tverdek; Javier A Adachi; Victor Mulanovich; Kenneth V Rolston; Issam I Raad; Roy F Chemaly Journal: Oncologist Date: 2012-06-15
Authors: Cheol-In Kang; Jae-Hoon Song; Doo Ryeon Chung; Kyong Ran Peck; Joon-Sup Yeom; Jun Seong Son; Yu Mi Wi Journal: Support Care Cancer Date: 2011-12-23 Impact factor: 3.603
Authors: Kathleen D Triplett; Srijana Pokhrel; Moriah J Castleman; Seth M Daly; Bradley O Elmore; Jason A Joyner; Geetanjali Sharma; Guy Herbert; Matthew J Campen; Helen J Hathaway; Eric R Prossnitz; Pamela R Hall Journal: Sci Rep Date: 2019-02-04 Impact factor: 4.379
Authors: Huda M Al-Mutairi; Oluwaseun Egunsola; Afaf Almutairi; Salha M Al-Dossary; Rana S Alshammasi; Dalal S Al-Dossari; Sheraz Ali Journal: Saudi Med J Date: 2021-12 Impact factor: 1.422